TRAZODONE HYDROCHLORIDE tablet

Trazodone Hydrochloride by

Drug Labeling and Warnings

Trazodone Hydrochloride by is a Prescription medication manufactured, distributed, or labeled by Aurolife Pharma, LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    WARNING:SUICIDAL THOUGHTS AND BEHAVIORS

    WARNING: SUICIDAL THOUGHTS and BEHAVIORS

    Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.  Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)]. Trazodone Hydrochloride Tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4)].

  • 1 INDICATIONS AND USAGE

    Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Dose Selection


    An initial dose of 150 mg/day in divided doses is suggested. The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage.
    The dose may be increased by 50 mg/day every 3 to 4 days. The maximum dose for outpatients usually should not exceed 400 mg/day in divided doses. Inpatients (i.e., more severely depressed patients) may be given up to but not in excess of 600 mg/day in divided doses.
    Once an adequate response has been achieved, dosage may be gradually reduced, with subsequent adjustment depending on therapeutic response.

    2.2 Important Administration Instructions

    Trazodone hydrochloride tablets can be swallowed whole or administered as a half tablet by breaking the tablet along the score line. Trazodone hydrochloride tablets should be taken shortly after a meal or light snack.

    2.3 Screen for Bipolar Disorder Prior to Starting Trazodone hydrochloride tablets

    Prior to initiating treatment with Trazodone hydrochloride tablets or another antidepressant, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see Warnings and Precautions (5.7)].

    2.4 Switching to or from Monoamine Oxidase Inhibitor Antidepressant

    At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) antidepressant and initiation of Trazodone hydrochloride tablets. In addition, at least 14 days must elapse after stopping Trazodone hydrochloride tablets before starting an MAOI antidepressant [see Contraindications (4), Warnings and Precautions (5.2)].

    2.5 Dosage Recommendations for Concomitant Use with Strong CYP3A4 Inhibitors or Inducers


    Coadministration with Strong CYP3A4 Inhibitors
    Consider reducing Trazodone hydrochloride tablets dose based on tolerability when Trazodone  coadministered with a strong CYP3A4 inhibitor [see Drug Interactions (7.1)].
    Coadministration with Strong CYP3A4 Inducers
    Consider increasing Trazodone hydrochloride tablets dose based on therapeutic response when Trazodone coadministered with a strong CYP3A4 inducer [see Drug Interactions (7.1)].

    2.6 Discontinuation of Treatment with Trazodone hydrochloride tablets

    Adverse reactions may occur upon discontinuation of Trazodone hydrochloride tablets [SeeWarnings and Precautions (5.8)]. Gradually reduce the dosage rather than stopping Trazodone hydrochloride tablets abruptly whenever possible.

  • 3 DOSAGE FORMS AND STRENGTHS

    Trazodone hydrochloride tablets,USP are available in the following strengths:

    • 50 mg: White to off-white, round, biconvex, uncoated tablets, debossed with ‘J’ and ‘43’ on either side of scoreline (functional) on one side and plain on the other side.
    • 100 mg: White to off-white, round, biconvex, uncoated tablets, debossed with ‘J’ and ‘44’ on either side of scoreline (functional) on one side and plain on the other side.
    • 150 mg: White to off-white, oval, flat faced, beveled-edge, uncoated tablets with one side scored (functional) with full bisect debossed with ‘J’ and ‘45’ on either side and having two partial trisect on one side and plain on the other side.
    • 300 mg: White to off-white, oval, flat faced, beveled-edge, uncoated tablets with one side scored (functional) with full bisect debossed with ‘J’ and ‘46’ on either side and having two partial trisect on one side and plain on the other side.
  • 4 CONTRAINDICATIONS

    Trazodone hydrochloride tablets are contraindicated in:

    • Patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2), Drug Interactions (7.1)].
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients


    In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in pediatric and young adult patients was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 1.
    No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on suicide.
    Table 1: Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients

    Age   Range   (years) Drug-Placebo   Difference  in   Number of Patients  of   Suicidal   Thoughts  or Behaviors  per 1000   Patients   Treated
      Increases Compared to   Placebo  
          <18  14   additional   patients
           18-24  5   additional   patients
      Decreases   Compared to Placebo  
           25-64  1   fewer patient
          ≥65    6   fewer patients


    It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adult patients extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression.
    Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing Trazodone hydrochloride tablets, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

    5.2 Serotonin Syndrome


    Serotonin-norepinephrine reuptake inhibitors (SNRIs) and SSRIs, including Trazodone, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications(4), Drug Interactions (7.1)]. Serotonin syndrome can also occur when these drugs are used alone.

    Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

    The concomitant use of Trazodone with MAOIs is contraindicated. In addition, do not initiate Trazodone hydrochloride tablets in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Trazodone, discontinue Trazodone  before initiating treatment with the MAOI [seeContraindications (4), Drug Interactions (7.1)].

    Monitor all patients taking Trazodone for the emergence of serotonin syndrome. Discontinue treatment with Trazodone and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of Trazodone with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.

    5.3 Cardiac Arrhythmias


    Clinical studies indicate that trazodone hydrochloride may be arrhythmogenic in patients with preexisting cardiac disease. Arrhythmias identified include isolated PVCs, ventricular couplets, tachycardia with syncope, and torsade de pointes. Postmarketing events, including torsade de pointes have been reported at doses of 100 mg or less with the immediate-release form of Trazodone. Trazodone should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval. Trazodone are not recommended for use during the initial recovery phase of myocardial infarction. Caution should be used when administering Trazodone to patients with cardiac disease and such patients should be closely monitored, since antidepressant drugs (including Trazodone hydrochloride tablets) may cause cardiac arrhythmias [see Adverse Reactions (6.2)].

    Trazodone prolongs the QT/QTc interval. The use of Trazodone should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). Concomitant administration of drugs may increase the risk of cardiac arrhythmia [see Drug Interactions (7.1)].

    5.4 Orthostatic Hypotension and Syncope

    Hypotension, including orthostatic hypotension and syncope has been reported in patients receiving trazodone hydrochloride. Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug.

    5.5 Increased Risk of Bleeding


    Drugs that interfere with serotonin reuptake inhibition, including Trazodone, increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk.

    Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.

    Inform patients about the risk of bleeding associated with the concomitant use of Trazodone and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing Trazodone hydrochloride tablets.

    5.6 Priapism


    Cases of priapism (painful erections greater than 6 hours in duration) have been reported in men receiving Trazodone. Priapism, if not treated promptly, can result in irreversible damage to the erectile tissue. Men who have an erection lasting greater than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention [see Adverse Reactions (6.2), Overdosage (10)].

    Trazodone should be used with caution in men who have conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or in men with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie’s disease).

    5.7 Activation of Mania or Hypomania

    In patients with bipolar disorder, treating a depressive episode with Trazodone or another antidepressant may precipitate a mixed/manic episode. Activation of mania/hypomania has been reported in a small proportion of patients with major affective disorder who were treated with antidepressants. Prior to initiating treatment with Trazodone hydrochloride tablets, screen patients for any personal or family history of bipolar disorder, mania, or hypomania [see Dosage and Administration (2.3)].

    5.8 Discontinuation Syndrome

    Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include: nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible [See Dosage and Administration (2.6)].

    5.9 Potential for Cognitive and Motor Impairment

    Trazodone hydrochloride tablets may cause somnolence or sedation and may impair the mental and/or physical ability required for the performance of potentially hazardous tasks. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that the drug treatment does not affect them adversely.

    5.10 Angle-Closure Glaucoma

    The pupillary dilation that occurs following use of many antidepressant drugs including Trazodone hydrochloride tablets may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Avoid use of antidepressants, including Trazodone hydrochloride tablets, in patients with untreated anatomically narrow angles.

    5.11 Hyponatremia


    Hyponatremia may occur as a result of treatment with SNRIs and SSRIs, including Trazodone. Cases with serum sodium lower than 110 mmol/L have been reported. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).

    In patients with symptomatic hyponatremia, discontinue Trazodone hydrochloride tablets and institute appropriate medical intervention. Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations (8.5)].

  • 6 ADVERSE REACTIONS


    The following serious adverse reactions are described elsewhere in the labeling:


    6.1 Clinical Studies Experience


    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
    Table 2: Common Adverse Reactions Occurring in ≥ 2% of Trazodone-treated Patients and Greater than the Rate of Placebo-Treated Patients as Observed in Controled Clinical Studies

     
    		Inpatients
    		Outpatients
     
    		Trazodone Hydrochloride Tablets
    N=142
    		Placebo N=95
    		Trazodone Hydrochloride Tablets
    =157
    		Placebo N=158
    Allergic 
    Skin Condition/Edema
    		3%
    		1%
    		7%
    		1%
    Autonomic 
    Blurred Vision
    		6%
    		4%
    		15%
    		4%
    Constipation
    		7%
    		4%
    		8%
    		6%
    Dry Mouth
    		15%
    		8%
    		34%
    		20%
    Cardiovascular 
    Hypertension
    		20%
    		1%
    		1%
    		*
    Hypotension
    		7%
    		1%
    		4%
    		0
    Syncope
    		3%
    		2%
    		5%
    		1%
    CNS 
    Confusion
    		5%
    		0
    		6%
    		8%
    Decreased Concentration
    		3%
    		2%
    		1%
    		0
    Disorientation
    		2%
    		0
    		*
    		0
    Fatigue
    		11%
    		4%
    		6%
    		3%
    Headache
    		10%
    		5%
    		20%
    		16%
    Nervousness
    		15%
    		11%
    		6%
    		8%
    Gastrointestinal 
    Abdominal/Gastric Disorder
    		4%
    		4%
    		6%
    		4%
    Diarrhea
    		0
    		1%
    		5%
    		1%
    Nausea/Vomiting
    		10%
    		1%
    		13%
    		10%
    Musculoskeletal
    		 
    		 
    		 
    		 
    Aches/Pains
    		6%
    		3%
    		5%
    		3%
    Neurological 
    		 
    		 
    		 
    		 
    Incoordination
    		5%
    		0
    		2%
    		*
    Tremors
    		3%
    		1%
    		5%
    		4%
    Other 
    Eyes Red/Tired/Itching
    		3%
    		0
    		0
    		0
    Head Full-Heavy
    		3%
    		0
    		0
    		0
    Malaise
    		3%
    		0
    		0
    		0
    Nasal/Sinus Congestion
    		3%
    		0
    		6%
    		3%
    Weight Gain
    		1%
    		0
    		5%
    		2%
    Weight Loss
    		*
    		3%
    		6%
    		3%



    Other adverse reactions occurring at an incidence of <2% with the use of trazodone hydrochloride in the controlled clinical studies: akathisia, allergic reaction, anemia, chest pain, delayed urine flow, early menses, flatulence, hallucinations/delusions, hematuria, hypersalivation, hypomania, impaired memory, impaired speech, impotence, increased appetite, increased libido, increased urinary frequency, missed periods, muscle twitches, numbness, paresthesia, retrograde ejaculation, shortness of breath, and tachycardia/palpitations. Occasional sinus bradycardia has occurred in long-term studies.

    6.2 Post marketing Experience


    The following adverse reactions have been identified during post-approval use of Trazodone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure:

    Blood and lymphatic system disorders:     hemolytic anemia, leukocytosis

    Cardiac disorders: cardiospasm, congestive heart failure, conduction block, orthostatic hypotension and syncope, palpitations, bradycardia, atrial fibrillation, myocardial infarction, cardiac arrest, arrhythmia, ventricular ectopic activity, including ventricular tachycardia and QT prolongation.  Prolonged QT interval, torsade de pointes, and ventricular tachycardia have been reported at doses of 100 mg per day or less [see Warnings and Precautions (5.3)].
    Endocrine disorders: inappropriate ADH syndrome
    Eye disorders: diplopia
    Gastrointestinal disorders: increased salivation, nausea/vomiting
    General disorders and administration site conditions: chills, edema, unexplained death, weakness 
    Hepatobiliary disorders: cholestasis, jaundice, hyperbilirubinemia, liver enzyme alterations 
    Investigations: increased amylase
    Metabolism and nutrition disorders: methemoglobinemia
    Nervous system disorders: aphasia, ataxia, cerebrovascular accident, extrapyramidal symptoms, grand mal seizures, paresthesia, tardive dyskinesia, vertigo
    Psychiatric disorders: abnormal dreams, agitation, anxiety, hallucinations, insomnia, paranoid reaction, psychosis, stupor
    Renal and urinary disorders: urinary incontinence, urinary retention
    Reproductive system and breast disorders: breast enlargement or engorgement, clitorism, lactation, priapism [see Warnings and Precautions (5.6)]
    Respiratory, thoracic and mediastinal disorders: apnea
    Skin and subcutaneous tissue disorders: alopecia, hirsutism, leukonychia, pruritus, psoriasis, rash, urticaria
    Vascular disorders: vasodilation

  • 7 DRUG INTERACTIONS

    7.1 Drugs Having Clinically Important Interactions With Trazodone hydrochloride

    Table 3: Clinically Important Drug Interactions with Trazodone hydrochloride tablets

    Monoamine   Oxidase   Inhibitors   (MAOIs) 
    Clinical  Impact: 
    		 The   concomitant use  of   MAOIs   and   serotonergic   drugs including   Trazodone hydrochloride tablets   increases the  risk  of   serotonin   syndrome. 
    Intervention: 
    		 Trazodone hydrochloride tablets  is   contraindicated   in   patients   taking   MAOIs, including   MAOIs  such   as   linezolid  or  intravenous methylene   blue [see    Contraindications   (4) , Dosage   and   Administration   (2.3, 2.4),  and  Warnings and Precautions   (5.2) ]. 
    Examples: 
    		 isocarboxazid, moclobemide,   phenelzine,   selegiline, tranylcypromine 
    Other Serotonergic   Drugs 
    Clinical  Impact: 
    		 The   concomitant use  of   serotonergic   drugs including   Trazodone hydrochloride tablets  and  other   serotonergic   drugs   increases   the   risk of   serotonin   syndrome. 
    Intervention: 
    		 Monitor patients for   signs   and   symptoms of   serotonin   syndrome, particularly during   Trazodone hydrochloride tablets   initiation.   If serotonin   syndrome   occurs, consider   discontinuation  of DESYREL  and/or   concomitant serotonergic   drugs   [see    Warnings and   Precautions   (5.2) ]. 
    Examples: 
    		 triptans,   antidepressants   (tricyclic   and   serotonin   uptake   inhibitors),   fentanyl,   lithium, tramadol,   tryptophan, buspirone, and   St.   John's  Wort 
    Antiplatelet Agents  and   Anticoagulants 
    Clinical  Impact: 
    		 Serotonin   release  by platelets plays   an   important role  in   hemostasis.   The   concurrent use   of an   antiplatelet   agent or   anticoagulant with Trazodone hydrochloride tablets may potentiate   the   risk of   bleeding. 
    Intervention: 
    		Inform patients  of  the   increased   risk  of   bleeding   with   the   concomitant use  of   Trazodone hydrochloride tablets and   antiplatelet   agents and   anticoagulants.  For   patients   taking   warfarin, carefully monitor  the   international   normalized   ratio   (INR) when   initiating  or   discontinuing   Trazodone hydrochloride tablets [see    Warnings  and   Precautions   (5.5) ]. 
    Examples: 
    		 warfarin, rivaroxaban, dabigatran, clopidogrel 
    Strong CYP3A4   Inhibitors 
    Clinical  Impact: 
    		 The   concomitant use  of   Trazodone hydrochloride tablets  and   strong   CYP3A4   inhibitors increased  the   exposure   of   trazodone   compared   to   the   use  of Trazodone hydrochloride tablets   alone. 
    Intervention: 
    		If Trazodone hydrochloride tablets is   used   with  a   potent CYP3A4   inhibitor, the   risk of adverse   reactions, including   cardiac arrhythmias, may be   increased  and  a   lower dose  of Trazodone hydrochloride tablets  should  be   considered  [see    Dosage   and   Administration  (2.5),    Warnings   and   Precautions   (5.3)] . 
    Examples: 
    		 itraconazole, ketoconazole,   clarithromycin, indinavir 
    Strong CYP3A4   Inducers 
    Clinical  Impact: 
    		 The   concomitant use  of   Trazodone hydrochloride tablets  and   strong   CYP3A4   inducers decreased  the   exposure  of   trazodone   compared   to   the   use  of Trazodone hydrochloride tablets   alone. 
    Intervention: 
    		 Patients should  be  closely monitored  to  see  if there  is  a   need  for an   increased   dose  of Trazodone hydrochloride tablets   when   taking   CYP3A4   inducers   [see   Dosage   and   Administration   (2.5)]. 
    Examples: 
    		 rifampin,   carbamazepine, phenytoin, St.   John’s   wort
    Digoxin and Phenytoin 
    Clinical  Impact: 
    		 Digoxin  and   phenytoin  are   narrow   therapeutic index  drugs. Concomitant  use  of Trazodone hydrochloride tablets can  increase   digoxin  or phenytoin   concentrations. 
    Intervention: 
    		 Measure   serum   digoxin  or phenytoin   concentrations before   initiating   concomitant use  of   Trazodone hydrochloride tablets. Continue   monitoring  and   reduce   digoxin  or   phenytoin   dose   as   necessary. 
    Examples: 
    		 digoxin, phenytoin 
    Central Nervous   System   (CNS) Depressants 
    Clinical  Impact: 
    		 Desyrel   may enhance  the   response   CNS depressants. 
    Intervention: 
    		 Patients should  be   counseled   that Trazodone hydrochloride tablets may   enhance   the   response   to   alcohol,   barbiturates,  and  other CNS   depressants. 
    Examples: 
    		 alcohol,   barbiturates 
    QT Interval Prolongation 
    Clinical  Impact: 
    		 Concomitant use  of drugs that   prolong   the   QT   interval  may add  to   the   QT   effects of Trazodone hydrochloride tablets  and   increase  the   risk   of cardiac   arrhythmia. 
    Intervention: 
    		 Avoid  the  use  of Trazodone hydrochloride tablets in   combination   with   other drugs known  to   prolong   QTc   [see    Warnings and   Precautions   (5.3) ] . 
    Examples: 
    		Class  1A antiarrhythmics: quinidine, procainamide, disopyramide;  Class  3   antiarrhythmics: amiodarone, sotalol;  Antipsychotics: ziprasidone,   chlorpromazine, thioridazine;   Antibiotics:   gatifloxacin 
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

     


    Pregnancy Exposure Registry
    There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405- 6185 or visiting online at https://womensmentalhealth.org/clinical-and-research programs/pregnancy registry/antidepressants/


    Risk Summary
    Published prospective cohort studies, case series, and case reports over several decades with Trazodone Hydrochloride Tablets use in pregnant women have not identified any drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). Trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in the rat when given at dose levels approximately 7.3 to 11 times the maximum recommended human dose (MRHD) of 400 mg/day in adults on a mg/m2  basis. There was also an increase in congenital anomalies in the rabbit at approximately 7.3 to 22 times the MRHD on a mg/m2 basis (see Data).


    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.


    Clinical Considerations


    Disease-associated maternal and/or embryofetal risk
    A prospective, longitudinal study followed 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. The women who discontinued antidepressants during pregnancy were more likely to experience a relapse of major depression that women who continued antidepressants. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.


    Data


    Human Data
    While available studies cannot definitively establish the absence of risk, published data from prospective cohort studies, case series, and case reports over several decades have not identified an association with trazodone use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. All available studies have methodological limitations, including small sample size and inconsistent comparator groups.


    Animal Data
    No teratogenic effects were observed when trazodone was given to pregnant rats and rabbits during the period of organogenesis at oral doses up to 450 mg/kg/day. This dose is 11 and 22 times, in rats and rabbits, respectively, the maximum recommended human dose (MRHD) of 400 mg/day in adults on a mg/m2 basis. Increased fetal resorption and other adverse effects on the fetus in rats at 7.3 to 11 times the MRHD and increase in congenital anomalies in rabbits at 7.3 to 22 times the MRHD on a mg/m2 basis were observed.  No further details on these studies are available.



    8.2 Lactation

    Risk Summary

    Data from published literature report the transfer of trazodone into human milk. There are no data on the effect of trazodone on milk production. Limited data from post marketing reports have not identified and association of adverse effects on the breastfed child.

    The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Trazodone Hydrochloride Tablets and any potential adverse effects on the breastfed child from Trazodone Hydrochloride Tablets or from the underlying maternal condition.

    8.4 Pediatric Use

     Safety and effectiveness in the pediatric population have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients [see Boxed Warning, Warnings and Precautions (5.1)].

    8.5 Geriatric Use

    Reported clinical literature and experience with trazodone has not identified differences in responses between elderly and younger patients. However, as experience in the elderly with trazodone hydrochloride is limited, it should be used with caution in geriatric patients.

    Serotonergic antidepressants have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse reaction [see Warnings and Precautions (5.11)].

    8.6 Renal Impairment

    Trazodone has not been studied in patients with renal impairment. Trazodone should be used with caution in this population.

    8.7 Hepatic Impairment

    Trazodone has not been studied in patients with hepatic impairment. Trazodone should be used with caution in this population.

  • 9 DRUG ABUSE AND DEPENDENCE

    9.1 Controlled Substance

    Trazodone hydrochloride tablets are not a controlled substance.

    9.2 Abuse

    Although trazodone hydrochloride has not been systematically studied in preclinical or clinical studies for its potential for abuse, no indication of drug-seeking behavior was seen in the clinical studies with trazodone hydrochloride.

  • 10 OVERDOSAGE


    Death from overdose has occurred in patients ingesting Trazodone and other CNS depressant drugs concurrently (alcohol; alcohol and chloral hydrate and diazepam; amobarbital; chlordiazepoxide; or meprobamate).
    The most severe reactions reported to have occurred with overdose of Trazodone alone have been priapism, respiratory arrest, seizures, and ECG changes, including QT prolongation. The reactions reported most frequently have been drowsiness and vomiting. Overdosage may cause an increase in incidence or severity of any of the reported adverse reactions.
    There is no specific antidote for trazodone hydrochloride overdose. In managing overdosage, consider the possibility of multiple drug involvement. For current information on the management of poisoning or overdose, contact a poison control center (1-800-222-1222 or www.poison.org).

  • 11 DESCRIPTION


    Trazodone hydrochloride tablets for oral administration contain trazodone hydrochloride, a selective serotonin reuptake inhibitor and 5HT2 receptor antagonist. Trazodone hydrochloride is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1piperazinyl]propyl]-1,2,4-triazolo [4,3-a]pyridin-3(2H)-one hydrochloride. It is a white odorless crystalline powder which is freely soluble in water. The structural formula is represented as follows:
    structure



    Molecular Formula: C19H22CIN5O HCl
    Molecular Weight: 408.33

    Each tablet, for oral administration, contains 50 mg, 100 mg, 150 mg or 300 mg of trazodone hydrochloride, USP. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized starch (physically modified corn (maize) starch), sodium lauryl sulfate, and sodium starch glycolate.

    Meets USP Dissolution Test 2. 


  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The mechanism of trazodone’s antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS. Trazodone is both a selective serotonin reuptake inhibitor (SSRI) and a 5HT2 receptor antagonist and the net result of this action on serotonergic transmission and its role in trazodone’s antidepressant effect is unknown.

    12.2 Pharmacodynamics

    Preclinical studies have shown that trazodone selectively inhibits neuronal reuptake of serotonin (Ki = 367 nM) and acts as an antagonist at 5-HT-2A (Ki = 35.6 nM) serotonin receptors. Trazodone is also an antagonist at several other monoaminergic receptors including 5-HT2B (Ki = 78.4 nM), 5-HT2C (Ki = 224 nM), α1A (Ki = 153 nM), α2C (Ki = 155 nM) receptors and it is a partial agonist at 5HT1A (Ki = 118 nM) receptor.

    Trazodone antagonizes alpha 1-adrenergic receptors, a property which may be associated with postural hypotension.

    12.3 Pharmacokinetics


    Absorption
    In humans, trazodone hydrochloride is absorbed after oral administration without selective localization in any tissue. When trazodone hydrochloride is taken shortly after ingestion of food, there may be an increase in the amount of drug absorbed, a decrease in maximum concentration and a lengthening in the time to maximum concentration. Peak plasma levels occur approximately one hour after dosing when trazodone hydrochloride is taken on an empty stomach or 2 hours after dosing when taken with food.

    Metabolism
    In vitro studies in human liver microsomes show that trazodone is metabolized, via oxidative cleavage, to an active metabolite, mchlorophenylpiperazine (mCPP) by CYP3A4. Other metabolic pathways that may be involved in the metabolism of trazodone have not been well characterized. Trazodone is extensively metabolized; less than 1% of an oral dose is excreted unchanged in the urine.

    Elimination
    In some patients trazodone may accumulate in the plasma.

    Protein Binding
    Trazodone is 89 to 95% protein bound in vitro at concentrations attained with therapeutic doses in humans.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis,Mutagenesis,Impairment Of Fertility


    Carcinogenesis
    No drug- or dose-related occurrence of carcinogenesis was evident in rats receiving trazodone in daily oral doses up to 7.3 times the maximum recommended human dose (MRSD) of 400 mg/day on mg/m2 basis.


    Mutagenesis
    No genotoxicity studies were conducted with trazodone.


    Impairment of Fertility
    Trazodone has no effect on fertility in rats at doses up to 6 times the MRHD on mg/m2 basis in adolescents.



  • 14 CLINICAL STUDIES

    The efficacy and safety of trazodone hydrochloride were established from inpatient and outpatient trials of the trazodone immediate release formulation in the treatment of major depressive disorder.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING


    Trazodone Hydrochloride Tablets, USP 50 mg are white to off-white, round, biconvex, uncoated tablets, debossed with ‘J’ and ‘43’ on either side of scoreline (functional) on one side and plain on the other side.
    Bottles of 30                                        NDC: 13107-079-30
    Bottles of 100                                      NDC: 13107-079-01
    Bottles of 500                                      NDC: 13107-079-05
    Bottles of 1,000                                   NDC: 13107-079-99

    Trazodone Hydrochloride Tablets, USP 100 mg     are white to off-white, round, biconvex, uncoated tablets, debossed with ‘J’ and ‘44’ on either side of scoreline (functional) on one side and plain on the other side.
    Bottles of 30                                       NDC: 13107-080-30
    Bottles of 100                                     NDC: 13107-080-01
    Bottles of 500                                     NDC: 13107-080-05
    Bottles of 1,000                                  NDC: 13107-080-99

    Trazodone Hydrochloride Tablets, USP 150 mg are white to off-white, oval, flat faced, beveled-edge, uncoated tablets with one side scored (functional) with full bisect debossed with ‘J’ and ‘45’ on either side and having two partial trisect on one side and plain on the other side.
    Bottles of 20                                      NDC: 13107-081-20
    Bottles of 100                                    NDC: 13107-081-01
    Bottles of 500                                    NDC: 13107-081-05
    Bottles of 1,000                                 NDC: 13107-081-99

    Directions for using the correct score when breaking the tablet, please refer to the following:
    -For 50 mg, break the score on either the left or right side of the tablet (one-third of a tablet).


    score1

    -For 75 mg, break the score down the middle of the tablet (one-half of a tablet).


    score2

    -For 100 mg, break the score on either the left or right side of the tablet (two-thirds of a tablet).


    score3

    -For 150 mg, use the entire tablet.


    score4


    Trazodone Hydrochloride Tablets, USP 300 mg are white to off-white, oval, flat faced, beveled-edge, uncoated tablets with one side scored (functional) with full bisect debossed with ‘J’ and ‘46’ on either side and having two partial trisect on one side and plain on the other side.
    Bottles of 100                                   NDC: 13107-082-01
    Bottles of 500                                   NDC: 13107-082-05
    Directions for using the correct score when breaking the tablet, please refer to the following:
    -For 100 mg, break the score on either the left or right side of the tablet (one-third of a tablet)


    score5

    -For 150 mg, break the score down the middle of the tablet (one-half of a tablet).


    score6

    -For 200 mg, break the score on either the left or right side of the tablet (two-thirds of a tablet).


    score7

    -For 300 mg, use the entire tablet.


    score8

    Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15ºC and 30ºC (59°F to 86ºF) [see USP Controlled Room Temperature]. Dispense with a child-resistant closure in a tight, light-resistant container.




  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Medication Guide).


    Suicidal Thoughts and Behaviors

    Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down and instruct them to report such symptoms to the healthcare provider [see Box Warningand Warnings and Precautions (5.1)].


    Dosage and Administration

    Advise patients that Trazodone hydrochloride tablets should be taken shortly after a meal or light snack. Advise patients regarding the importance of following dosage titration instructions [see Dosage and Administration (2)].


    Serotonin Syndrome

    Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of Trazodone hydrochloride tablets with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Patients should contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome [see Warnings and Precautions (5.2) and Drug Interactions (7)].


    Activation of Mania/Hypomania

    Advise patients and their caregivers to observe for signs of activation of mania/hypomania and instruct them to report such symptoms to the healthcare provider [see Warnings and Precautions (5.7)].


    Increased Risk of Bleeding

    Inform patients about the concomitant use of Trazodone hydrochloride tablets with aspirin, NSAIDs, other antiplatelet drugs, warfarin, or other anticoagulants because the combined use of drugs that interfere with serotonin reuptake and these medications has been associated with an increased risk of bleeding. Advise them to inform their health care providers if they are taking or planning to take any prescription or over-the-counter medications that increase the risk of bleeding [see Warnings and Precautions (5.5)].


    Discontinuation Syndrome

    Advise patients not to abruptly discontinue Trazodone hydrochloride tablets and to discuss any tapering regimen with their healthcare provider. Adverse reactions can occur when Trazodone hydrochloride tablets are discontinued [see Warnings and Precautions (5.8)].


    Concomitant Medications

    Advise patients to inform their health care providers if they are taking, or plan to take any prescription or over-the-counter medications since there is a potential for interactions [see Drug Interactions (7.1)].

    Dispense with Medication Guide available at www.aurobindousa.com/product-medication-guides
     Distributed by:
    Aurobindo Pharma USA, Inc.
    279 Princeton-Hightstown Road
    East Windsor, NJ 08520

    Revised: 01/2020

  • MEDICATION GUIDE

    Trazodone Hydrochloride Tablets, USP

    (traz' oh done hye'' droeklor' ide)


    What is the most important information I should know about Trazodone hydrochloride tablets?
    Antidepressant medicines, depression or other serious mental illnesses, and suicidal thoughts or actions: Talk to your healthcare provider about:


    • All risks and benefits of treatment with antidepressant medicines
    • All treatment choices for depression or other serious mental illnesses

    1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.
    2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions.
    Some people may have a higher risk of having suicidal thoughts or actions. These include people who have or have a family history of bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.
    3. How can I watch for and try to prevent suicidal thoughts and actions?


    • Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.
    • Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts or feelings.
    • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms.

    Call a healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you:


    • Thoughts about suicide or dying
    • Attempts to commit suicide
    • New or worse depression
    • New or worse anxiety
    • Feeling very agitated or restless
    • Panic attacks
    • Trouble sleeping (insomnia)
    • New or worse irritability
    • Acting aggressive, being angry or violent
    • Acting on dangerous impulses
    • An extreme increase in activity and talking (mania)
    • Other unusual changes in behavior or mood

    What else do I need to know about antidepressant medicines?


    • Never stop an antidepressant medicine without first talking to a healthcare provider. Stopping an antidepressant medicine suddenly can cause other symptoms.
    • Antidepressants are medicines used to treat depression and other illnesses. It is important to discuss all the risks of treatingdepression and also the risks of not treating it. You should discuss all treatment choices with your healthcare provider, not just the use of antidepressants.
    • Antidepressant medicines have other side effects. Talk to your healthcare provider about the side effects of your medicines.
    • Antidepressant medicines can interact with other medicines. Know all of the medicines that you take. Keep a list of all medicines to show your healthcare provider. Do not start new medicines without first checking with your healthcare provider.

    It is not known if Trazodone hydrochloride tablets are safe and effective in children.

    What are Trazodone hydrochloride tablets?
    Trazodone hydrochloride tablets are the prescription medicine used in adults to treat major depressive disorder (MDD). Trazodone hydrochloride belongs to a class of medicines known as SSRIs (or selective serotonin reuptake inhibitors).

    Do not take Trazodone hydrochloride tablets:


    • If you take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid, and intravenous methylene blue.
    • Do not take an MAOI within 2 weeks of stopping Trazodone hydrochloride tablets unless directed to do so by your healthcare provider.
    • Do not start Trazodone hydrochloride tablets if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your healthcareprovider.

    Before you take Trazodone hydrochloride tablets tell your healthcare provider about all of your medical conditions, including if you:


    • have heart problems, including QT prolongation or a family history of it
    • have ever had a heart attack
    • have bipolar disorder
    • have liver or kidney problems
    • have other serious medical conditions
    • are pregnant or plan to become pregnant. Trazodone hydrochloride tablets may harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.
      • If you become pregnant during treatment with Trazodone Hydrochloride Tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants.  You can register by calling 1-844-405-6185.
    • are breastfeeding or plan to breastfeed. It is not known if Trazodone hydrochloride tablets passes into your breast milk. You and your healthcare provider should decide if you will take Trazodone hydrochloride tablets or breastfeed.
    • have taken a Monoamine Oxidase Inhibitor (MAOI) or if you have stopped taking an MAOI in the last 2 weeks.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using Trazodone hydrochloride tablets with certain other medicines can affect each other causing serious side effects.
    Especially tell your healthcare provider if you take:


    • triptans used to treat migraine headache
    • medicines used to treat mood, anxiety, psychotic or thought disorders, including tricyclics, lithium, SSRIs, SNRIs, buspirone, orantipsychotics
    • tramadol
    • over-the-counter supplements such as tryptophan or St. John’s Wort
    • nonsteroidal anti-inflammatory drugs (NSAIDS)
    • aspirin
    • warfarin (Coumadin, Jantoven)
    • phenytoin (Mesantoin)
    • diuretics

    Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.
    How should I take Trazodone hydrochloride tablets?


    • Take Trazodone hydrochloride tablets exactly as your healthcare provider tells you.
    • Trazodone hydrochloride tablets should be taken shortly after a meal or light snack.
    • If you feel drowsy after taking Trazodone hydrochloride tablets, talk to your healthcare provider. Your healthcare provider may change your dose or the time of day you take your Trazodone hydrochloride tablets.
    • Do not stop taking Trazodone hydrochloride tablets without talking to your healthcare provider.
    • Trazodone hydrochloride tablets should be swallowed whole or broken in half along the score line. Do not chew or crush Trazodone hydrochloride tablets. Tell your healthcare provider if you cannot swallow trazodone either whole or as a half tablet.
    • If you take too much Trazodone hydrochloride tablets, call your healthcare provider, your Poison Control Center at 1-800-222-1222, or go to the nearest emergency room right away.

    What should I avoid while taking Trazodone hydrochloride tablets?


    • Do not drive, operate heavy machinery, or do other dangerous activities until you know how Trazodone hydrochloride tablets affects you.Trazodone hydrochloride tablets can slow your thinking and motor skills.
    • Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking Trazodone hydrochloride tablets until you talk with your healthcare provider. Trazodone hydrochloride tablets may make your sleepiness or dizziness worse if you take it with alcohol or other medicines that cause sleepiness or dizziness.

    What are the possible side effects of Trazodone hydrochloride tablets?
    Trazodone hydrochloride tablets can cause serious side effects or death, including:


    • See “What is the most important information I should know about Trazodone hydrochloride tablets?”
    • Serotonin syndrome. Symptoms of serotonin syndrome include: agitation, hallucinations, and problems with coordination, fast heartbeat, tight muscles, trouble walking, sweating, fever, nausea, vomiting, and diarrhea.
    • Irregular or fast heartbeat or faint (QT prolongation)
    • Low blood pressure. You feel dizzy or faint when you change positions (go from sitting to standing)
    • Unusual bruising or bleeding
    • Erection lasting for more than 6 hours (priapism)
    • Feeling high or in a very good mood, then becoming irritable, or having too much energy, feeling like you have to keep talking or do not sleep (mania).
    • Withdrawal symptoms. Symptoms of withdrawal can include anxiety, agitation, and sleep problems. Do not stop taking Trazodone
    • hydrochloride tablets without talking to your healthcare provider
    • Visual problems.

                  o eye pain

                  o changes in vision
                  o swelling or redness in or around the eye

    Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.



    • Low sodium in your blood (hyponatremia). Symptoms of hyponatremia include: headache, feeling weak, feeling confused, troubleconcentrating, memory problems and feeling unsteady when you walk.

    Get medical help right away, if you have any of the symptoms listed above.
    The most common side effects of Trazodone hydrochloride tablets include:


    • swelling
    • blurred vision
    • dizziness
    • sleepiness
    • tiredness
    • diarrhea
    • stuffy nose
    • weight loss

    These are not all the possible side effects of Trazodone hydrochloride tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
    How should I store Trazodone hydrochloride tablets?


    • Store Trazodone hydrochloride tablets at room temperature between 68°F to 77°F (20°C to 25°C).
    • Keep in tight container
    • Keep out of the light
    • Safely throw away medicine that is out of date or no longer needed.

    Keep Trazodone hydrochloride tablets and all medicines out of the reach of children.
    General information about the safe and effective use of Trazodone hydrochloride tablets.
    Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Trazodone hydrochloride tablets for a condition for which it was not prescribed. Do not give Trazodone hydrochloride tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Trazodone hydrochloride tablets that is written for health professionals.

    What are the ingredients in Trazodone hydrochloride tablets?
    Active ingredient: trazodone hydrochloride, USP
    Inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized starch (physically modified corn (maize) starch), sodium lauryl sulfate, and sodium starch glycolate.
    This Medication Guide has been approved by the U.S. Food and Drug Administration

    Dispense with Medication Guide available at www.aurobindousa.com/product-medication-guides
    Distributed by:
    Aurobindo Pharma USA, Inc.
    279 Princeton-Hightstown Road
    East Windsor, NJ 08520

    Revised: 01/2020

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-50 mg (30 Tablet Bottle)


    NDC: 13107-079-30

    TraZODONE Hydrochloride Tablets, USP


    50 mg
    Pharmacist:     "Dispense the Medication Guide provided separately to each patient."
    Rx only 30 Tablets


    trazodone50mg30ct
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-100 mg (30 Tablet Bottle)

    NDC: 13107-080-30
    TraZODONE Hydrochloride Tablets, USP
    100 mg
    Pharmacist    : "Dispense the Medication Guide provided separately to each patient."
    Rx only 30 Tablets

    trazodone100mg30ct


  • PACKAGE LABEL-PRINCIPAL DISPALY PANEL- 150 mg (20 Tablet Bottle)

    NDC: 13107-081-20
    TraZODONE Hydrochloride Tablets, USP
    150 mg
    Pharmacist:     "Dispense the Medication Guide provided separately to each patient."
    Rx only 20 Tablets

    trazodone150mg30ct



  • PACKAGE LABEL-PRINCIPAL DISPALY PANEL- 300 mg (100 Tablet Bottle)

    NDC: 13107-082-01
    TraZODONE Hydrochloride Tablets, USP
    300 mg
    Pharmacist    : "Dispense the Medication Guide provided separately to each patient."
    Rx only 100 Tablets


    trazodone300mg100ct

  • INGREDIENTS AND APPEARANCE
    TRAZODONE HYDROCHLORIDE 
    trazodone hydrochloride tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 13107-079
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    TRAZODONE HYDROCHLORIDE (UNII: 6E8ZO8LRNM) (TRAZODONE - UNII:YBK48BXK30) TRAZODONE HYDROCHLORIDE50 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    Product Characteristics
    ColorWHITE (white to off-white) Score2 pieces
    ShapeROUND (biconvex) Size7mm
    FlavorImprint Code J;43
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 13107-079-3030 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    2NDC: 13107-079-01100 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    3NDC: 13107-079-05500 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    4NDC: 13107-079-991000 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20485209/15/2015
    TRAZODONE HYDROCHLORIDE 
    trazodone hydrochloride tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 13107-080
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    TRAZODONE HYDROCHLORIDE (UNII: 6E8ZO8LRNM) (TRAZODONE - UNII:YBK48BXK30) TRAZODONE HYDROCHLORIDE100 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    Product Characteristics
    ColorWHITE (white to off-white) Score2 pieces
    ShapeROUND (biconvex) Size10mm
    FlavorImprint Code J;44
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 13107-080-3030 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    2NDC: 13107-080-01100 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    3NDC: 13107-080-05500 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    4NDC: 13107-080-991000 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20485209/15/2015
    TRAZODONE HYDROCHLORIDE 
    trazodone hydrochloride tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 13107-081
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    TRAZODONE HYDROCHLORIDE (UNII: 6E8ZO8LRNM) (TRAZODONE - UNII:YBK48BXK30) TRAZODONE HYDROCHLORIDE150 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    Product Characteristics
    ColorWHITE (white to off-white) Score3 pieces
    ShapeOVAL (biconvex) Size17mm
    FlavorImprint Code J;45
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 13107-081-2020 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    2NDC: 13107-081-01100 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    3NDC: 13107-081-05500 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    4NDC: 13107-081-991000 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20485209/15/2015
    TRAZODONE HYDROCHLORIDE 
    trazodone hydrochloride tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 13107-082
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    TRAZODONE HYDROCHLORIDE (UNII: 6E8ZO8LRNM) (TRAZODONE - UNII:YBK48BXK30) TRAZODONE HYDROCHLORIDE300 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    Product Characteristics
    ColorWHITE (white to off-white) Score3 pieces
    ShapeOVAL (biconvex) Size21mm
    FlavorImprint Code J;46
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 13107-082-01100 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    2NDC: 13107-082-05500 in 1 BOTTLE; Type 0: Not a Combination Product09/15/2015
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20485209/15/2015
    Labeler - Aurolife Pharma, LLC (829084461)
    Establishment
    NameAddressID/FEIBusiness Operations
    Aurolife Pharma, LLC829084461MANUFACTURE(13107-079, 13107-080, 13107-081, 13107-082)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.